ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,629.38
      -0.08%
      US Tech 100
      20,092.80
      -0.13%
      Dow Jones
      39,859.31
      0.35%
      Brent Oil
      84.665
      -0.45%
      Bitcoin
      58,285.05
      0.91%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Redhill Biopharma Ltd (RDHL)

      7. Redhill Biopharma Ltd (RDHL) News

      RDHL

      Redhill Biopharma (RDHL)

      Redhill Biopharma Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RDHL
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      01/25/20246:00AMPR Newswire (US)RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042NASDAQ:RDHLRedhill Biopharma Ltd
      12/20/20238:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      12/20/20238:45AMPR Newswire (US)RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaNASDAQ:RDHLRedhill Biopharma Ltd
      12/12/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      12/12/20237:00AMPR Newswire (US)RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:RDHLRedhill Biopharma Ltd
      12/06/20237:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      12/04/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      12/04/20237:00AMPR Newswire (US)RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 StudyNASDAQ:RDHLRedhill Biopharma Ltd
      12/01/20234:10PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      11/27/20237:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      11/27/20237:00AMPR Newswire (US)RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034NASDAQ:RDHLRedhill Biopharma Ltd
      11/16/202312:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      11/14/20238:00AMPR Newswire (US)RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital MarketNASDAQ:RDHLRedhill Biopharma Ltd
      10/27/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RDHLRedhill Biopharma Ltd
      10/26/20234:52PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RDHLRedhill Biopharma Ltd
      10/23/20234:06PMEdgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:RDHLRedhill Biopharma Ltd
      10/16/20234:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      10/13/20238:13AMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:RDHLRedhill Biopharma Ltd
      10/12/20234:05PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RDHLRedhill Biopharma Ltd
      10/10/20239:08AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      10/03/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      10/03/20237:00AMPR Newswire (US)RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo StudyNASDAQ:RDHLRedhill Biopharma Ltd
      09/29/20238:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      09/22/20234:17PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      09/22/20234:15PMPR Newswire (US)RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:RDHLRedhill Biopharma Ltd
      09/18/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      09/18/20237:00AMPR Newswire (US)RedHill Announces FDA sNDA Approval for Talicia®NASDAQ:RDHLRedhill Biopharma Ltd
      09/05/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
      09/05/20237:00AMPR Newswire (US)RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)NASDAQ:RDHLRedhill Biopharma Ltd
       Showing the most relevant articles for your search:NASDAQ:RDHL